Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients with Venous Thromboembolism in Europe

Starting date
December 14, 2016
Duration (months)
Department of Engineering for Innovation Medicine
Managers or local contacts
Lippi Giuseppe

Edoxaban is an orally administered anticoagulant that inhibits coagulation factor Xa. It has recently been approved by the European Medicines Agency EMA for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, as well as for the treatment of adult patients with venous thromboembolism including deep vein thrombosis and/or pulmonary embolism (after initial heparin lead-in), and the prevention of recurrent VTE.
This study aims to gather further insight into efficacy (i.e. symptomatic recurrent VTE) and safety (i.e. bleeding events, liver adverse events and other drug related adverse events) of the treatment with Edoxaban in an unselected patient population in routine clinical practice. Real worls evidence data of routine clinical practice use of Edoxaban up to 18 months will be collected in 2550 patients, treated by specialized as well as non-specialized physicians in hospitals and office based centres.


Funds: assigned and managed by an external body

Project participants

Giuseppe Lippi
Full Professor

Collaboratori esterni

Roberto Facchinetti
Azienda Ospedaliera Universitaria Integrata di Verona


Research facilities